Codex

Buy at the last available close of $277.56 on April 8, 2026; my probability-weighted 12-month value is $325, or 17.1% upside, with 4.9x weighted upside/downside and a 3.0% position size.

Current price uses the last local close in `data/prices_av.json` on April 8, 2026. The requested `research-codex.md`, `earnings_calendar.json`, and `analyst_estimates.json` files were not present, so the catalyst dates and consensus references below use the available local research and estimate files.

What's Next

There are only two real stock-moving checkpoints in the next four months: the April 30, 2026 earnings report and the July 1, 2026 CEO handoff. That is enough for a trade, but not enough for a full-size position, because both events are really tests of the same thing: can Cigna prove that Evernorth can absorb PBM pressure while Cigna Healthcare stays out of another medical-cost hole?

Days To Next Earnings

Last Close

$277.6

Consensus Target

$338

Consensus Upside

21.9%

No Results

**This is not a catalyst-rich story.** If April 30 is clean and July 1 is orderly, the next real proof point is the summer print. If April 30 disappoints, the cheap multiple will not save the stock in the near term.

The market is likely to care far more about three operating lines than about the headline revenue number: Evernorth pre-tax income, Cigna Healthcare medical care ratio, and whether 2026 adjusted EPS stays intact after the PBM reset started to compress sentiment in late 2025. The CEO transition matters mostly because it can either narrow or widen the governance discount; it is not a new strategy launch by itself.

The Verdict

CI is attractive here because the stock already discounts a lot of bad news at about 8.9x forward earnings, while the business still produces roughly $8.4 billion of free cash flow and keeps shrinking the share count. The edge is not hidden hypergrowth. The edge is that Cigna only needs stabilization, not perfection, for the stock to move from a punishment multiple toward a merely normal one.

Current Price

$277.6

Probability-Weighted Value

$325

▲ 17.2% Upside vs current

Weighted Asymmetry (x)

4.9

Position Size (%)

3.0

No Results

**Bull case: $380.** Evernorth absorbs PBM pressure without giving away the franchise, adjusted EPS reaches about $33, and the stock rerates to 11.5x because investors stop treating CI like a structurally impaired insurer.

**Base case: $331.** Evernorth still grows, Cigna Healthcare only stabilizes rather than improves sharply, and the multiple moves to 10.5x because the market gains confidence that the post-Medicare portfolio can hold around $31.5 of adjusted EPS.

**Bear case: $216.** Evernorth margin erosion proves the PBM reset is a pricing concession, stop-loss and IFP costs stay messy, and the stock falls to 8.0x on about $27 of adjusted EPS because investors conclude the discount was deserved.

What the market may still be missing is that CI does not need a heroic operating turn for the stock to work. If Evernorth keeps pre-tax income growing and Cigna Healthcare merely avoids another credibility break, the company can keep compounding per-share value through buybacks and cash generation even before a full rerating. Cheap alone is not the edge here; cheap plus decent execution is.

No Results

The position should stay small because the expected value is good but the path is narrow. There is no deep catalyst bench, governance is improving only partially, and the PBM reset still needs proof. A 3.0% position fits that mix: large enough to matter if the cheap multiple normalizes, small enough that another trust break does not damage the portfolio.

LEAPS / Options

No actionable options setup.

No Results

**Stock over options.** Open interest exists, but same-day volume is mostly zero and bid/ask spreads run roughly 5% to 10% of premium. That is too much friction to force a LEAPS thesis when the common stock already offers adequate upside.